Serina Therapeutics (SER) Cash from Financing Activities (2018 - 2025)

Serina Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at $481000.0 in Q4 2025.

• Quarterly Cash from Financing Activities fell 90.44% year-over-year to $481000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.4 million (up 31.79% YoY) and the FY2025 annual result came in at $17.4 million, up 31.79% from the prior year.
• Cash from Financing Activities slipped to $481000.0 in Q4 2025 per SER's latest filing, from $6.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $10.1 million in Q1 2023 and troughed at -$13000.0 in Q4 2023.
• A 5-year average of $2.7 million and a median of $1.8 million in 2021 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 100.87% in 2023, then soared 48890.91% in 2024.
• Over 5 years, Cash from Financing Activities stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then plunged by 100.87% to -$13000.0 in 2023, then surged by 38800.0% to $5.0 million in 2024, then sank by 90.44% to $481000.0 in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $481000.0, $6.4 million, and $5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.